- Home
- TPG vs TFX Comparison
TPG vs TFX Comparison
Compare TPG & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPG
- TFX
- Stock Information
- Founded
- TPG 1992
- TFX 1943
- Country
- TPG United States
- TFX United States
- Employees
- TPG N/A
- TFX N/A
- Industry
- TPG Investment Managers
- TFX Medical/Dental Instruments
- Sector
- TPG Finance
- TFX Health Care
- Exchange
- TPG Nasdaq
- TFX Nasdaq
- Market Cap
- TPG 6.6B
- TFX 5.3B
- IPO Year
- TPG 2022
- TFX N/A
- Fundamental
- Price
- TPG $50.55
- TFX $118.23
- Analyst Decision
- TPG Buy
- TFX Hold
- Analyst Count
- TPG 13
- TFX 10
- Target Price
- TPG $62.17
- TFX $176.50
- AVG Volume (30 Days)
- TPG 1.9M
- TFX 436.2K
- Earning Date
- TPG 08-05-2025
- TFX 07-31-2025
- Dividend Yield
- TPG 3.44%
- TFX 1.16%
- EPS Growth
- TPG N/A
- TFX N/A
- EPS
- TPG N/A
- TFX 3.20
- Revenue
- TPG $3,710,887,000.00
- TFX $3,010,144,000.00
- Revenue This Year
- TPG N/A
- TFX $2.98
- Revenue Next Year
- TPG $23.44
- TFX $4.84
- P/E Ratio
- TPG $16,212.23
- TFX $36.70
- Revenue Growth
- TPG 44.34
- TFX 0.29
- 52 Week Low
- TPG $37.52
- TFX $116.82
- 52 Week High
- TPG $72.98
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- TPG 55.28
- TFX 39.12
- Support Level
- TPG $48.67
- TFX $121.29
- Resistance Level
- TPG $51.56
- TFX $126.87
- Average True Range (ATR)
- TPG 1.39
- TFX 2.65
- MACD
- TPG 0.00
- TFX -0.17
- Stochastic Oscillator
- TPG 73.68
- TFX 15.71
About TPG TPG Inc.
TPG Inc is an alternative asset firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, and Market Solutions. TPG aims to build dynamic products and options for its clients while also instituting discipline and operational excellence across the investment and performance of its portfolio.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.